WO1993013079A1 - Quinazolines anti-folates - Google Patents
Quinazolines anti-folates Download PDFInfo
- Publication number
- WO1993013079A1 WO1993013079A1 PCT/US1992/010730 US9210730W WO9313079A1 WO 1993013079 A1 WO1993013079 A1 WO 1993013079A1 US 9210730 W US9210730 W US 9210730W WO 9313079 A1 WO9313079 A1 WO 9313079A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- group
- compound according
- making
- mmol
- Prior art date
Links
- 230000003432 anti-folate effect Effects 0.000 title abstract description 19
- 229940127074 antifolate Drugs 0.000 title abstract description 19
- 239000004052 folic acid antagonist Substances 0.000 title abstract description 19
- 150000003246 quinazolines Chemical class 0.000 title abstract description 13
- 150000001875 compounds Chemical class 0.000 claims abstract description 303
- 108010022394 Threonine synthase Proteins 0.000 claims abstract description 52
- 230000005764 inhibitory process Effects 0.000 claims abstract description 35
- 102000004419 dihydrofolate reductase Human genes 0.000 claims abstract description 33
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims abstract description 29
- 235000019152 folic acid Nutrition 0.000 claims abstract description 25
- 239000011724 folic acid Substances 0.000 claims abstract description 25
- 230000037353 metabolic pathway Effects 0.000 claims abstract description 22
- 229940014144 folate Drugs 0.000 claims abstract description 21
- 102000005497 Thymidylate Synthase Human genes 0.000 claims abstract description 19
- 230000000694 effects Effects 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 272
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 217
- 125000003118 aryl group Chemical group 0.000 claims description 206
- 239000000203 mixture Substances 0.000 claims description 167
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 140
- 229910052739 hydrogen Inorganic materials 0.000 claims description 100
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 83
- -1 quinazoline compound Chemical class 0.000 claims description 80
- 238000000034 method Methods 0.000 claims description 69
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims description 65
- 125000000217 alkyl group Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 230000008569 process Effects 0.000 claims description 40
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 39
- 238000006243 chemical reaction Methods 0.000 claims description 36
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims description 36
- 239000003153 chemical reaction reagent Substances 0.000 claims description 28
- AOJFQRQNPXYVLM-UHFFFAOYSA-N pyridin-1-ium;chloride Chemical compound [Cl-].C1=CC=[NH+]C=C1 AOJFQRQNPXYVLM-UHFFFAOYSA-N 0.000 claims description 26
- 238000007363 ring formation reaction Methods 0.000 claims description 26
- 238000002560 therapeutic procedure Methods 0.000 claims description 25
- FUQFHOLPJJETAP-UHFFFAOYSA-N carbamimidoyl chloride;hydron;chloride Chemical compound Cl.NC(Cl)=N FUQFHOLPJJETAP-UHFFFAOYSA-N 0.000 claims description 20
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims description 19
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 18
- 239000003112 inhibitor Substances 0.000 claims description 18
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 13
- 125000001424 substituent group Chemical group 0.000 claims description 13
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 claims description 11
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 11
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Chemical compound O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 102000004190 Enzymes Human genes 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 9
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 229940088598 enzyme Drugs 0.000 claims description 9
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 9
- 230000001028 anti-proliverative effect Effects 0.000 claims description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N benzopyrrole Natural products C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
- 125000005907 alkyl ester group Chemical group 0.000 claims description 6
- 230000000843 anti-fungal effect Effects 0.000 claims description 6
- 230000002682 anti-psoriatic effect Effects 0.000 claims description 6
- 230000000259 anti-tumor effect Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 230000002934 lysing effect Effects 0.000 claims description 6
- 229920001308 poly(aminoacid) Polymers 0.000 claims description 6
- 239000003242 anti bacterial agent Substances 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 239000003096 antiparasitic agent Substances 0.000 claims description 5
- 239000003638 chemical reducing agent Substances 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 5
- 239000012279 sodium borohydride Substances 0.000 claims description 5
- 229910000033 sodium borohydride Inorganic materials 0.000 claims description 5
- 241000124008 Mammalia Species 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 150000001413 amino acids Chemical group 0.000 claims description 4
- 230000000844 anti-bacterial effect Effects 0.000 claims description 4
- 230000000340 anti-metabolite Effects 0.000 claims description 4
- 230000002141 anti-parasite Effects 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 229940100197 antimetabolite Drugs 0.000 claims description 4
- 239000002256 antimetabolite Substances 0.000 claims description 4
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical group N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000001165 anti-coccidial effect Effects 0.000 claims description 3
- 230000000842 anti-protozoal effect Effects 0.000 claims description 3
- 229940124536 anticoccidial agent Drugs 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- 239000003224 coccidiostatic agent Substances 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 3
- 125000006501 nitrophenyl group Chemical group 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 claims description 3
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 2
- 239000002168 alkylating agent Substances 0.000 claims description 2
- 229940100198 alkylating agent Drugs 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 239000012298 atmosphere Substances 0.000 claims description 2
- HLYRMDDXFDINCB-UHFFFAOYSA-N carbon monoxide;iron Chemical group [Fe].[Fe].[Fe].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-].[O+]#[C-] HLYRMDDXFDINCB-UHFFFAOYSA-N 0.000 claims description 2
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 2
- 239000010439 graphite Substances 0.000 claims description 2
- 229910002804 graphite Inorganic materials 0.000 claims description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 2
- 239000000367 immunologic factor Substances 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 230000000394 mitotic effect Effects 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 2
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 2
- 239000003904 antiprotozoal agent Substances 0.000 claims 4
- 101000908713 Homo sapiens Dihydrofolate reductase Proteins 0.000 claims 2
- 239000003429 antifungal agent Substances 0.000 claims 2
- 229940125687 antiparasitic agent Drugs 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 125000001475 halogen functional group Chemical group 0.000 claims 2
- 150000002475 indoles Chemical class 0.000 claims 2
- 150000003254 radicals Chemical class 0.000 claims 2
- PIEXCQIOSMOEOU-UHFFFAOYSA-N 1-bromo-3-chloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Br)C(=O)N(Cl)C1=O PIEXCQIOSMOEOU-UHFFFAOYSA-N 0.000 claims 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims 1
- 108020001096 dihydrofolate reductase Proteins 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 239000012444 intercalating antibiotic Substances 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 abstract description 42
- 230000012010 growth Effects 0.000 abstract description 8
- 241000894006 Bacteria Species 0.000 abstract description 7
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 abstract description 4
- 244000005700 microbiome Species 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 224
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 168
- 239000007787 solid Substances 0.000 description 156
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 154
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 145
- 239000000047 product Substances 0.000 description 142
- 238000002360 preparation method Methods 0.000 description 136
- 229910001868 water Inorganic materials 0.000 description 134
- 239000000243 solution Substances 0.000 description 133
- 238000005481 NMR spectroscopy Methods 0.000 description 107
- 235000019439 ethyl acetate Nutrition 0.000 description 106
- 239000000377 silicon dioxide Substances 0.000 description 103
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 93
- 229910052757 nitrogen Inorganic materials 0.000 description 93
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 92
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 88
- 229910052717 sulfur Inorganic materials 0.000 description 82
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 80
- 229910052681 coesite Inorganic materials 0.000 description 77
- 229910052906 cristobalite Inorganic materials 0.000 description 77
- 229910052682 stishovite Inorganic materials 0.000 description 77
- 229910052905 tridymite Inorganic materials 0.000 description 77
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 71
- 239000000706 filtrate Substances 0.000 description 40
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 40
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 40
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 35
- 239000000284 extract Substances 0.000 description 32
- 239000012044 organic layer Substances 0.000 description 32
- 239000000538 analytical sample Substances 0.000 description 31
- 239000003921 oil Substances 0.000 description 31
- 235000019198 oils Nutrition 0.000 description 31
- 239000012267 brine Substances 0.000 description 30
- 235000011121 sodium hydroxide Nutrition 0.000 description 30
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 28
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 24
- 238000004587 chromatography analysis Methods 0.000 description 24
- SBZXBUIDTXKZTM-UHFFFAOYSA-N diglyme Chemical compound COCCOCCOC SBZXBUIDTXKZTM-UHFFFAOYSA-N 0.000 description 24
- 239000002244 precipitate Substances 0.000 description 23
- 239000003610 charcoal Substances 0.000 description 22
- 238000010992 reflux Methods 0.000 description 21
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 20
- 239000011541 reaction mixture Substances 0.000 description 20
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 18
- 238000003818 flash chromatography Methods 0.000 description 18
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 16
- 238000009835 boiling Methods 0.000 description 16
- 229910052794 bromium Inorganic materials 0.000 description 16
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 14
- 239000012043 crude product Substances 0.000 description 14
- 239000000725 suspension Substances 0.000 description 14
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 13
- 0 CC(CC1)CCC1NC* Chemical compound CC(CC1)CCC1NC* 0.000 description 13
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 13
- HPWJUEZFOUOUEO-UHFFFAOYSA-N 5-chloro-2-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=C(Cl)C=C1C#N HPWJUEZFOUOUEO-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 125000006239 protecting group Chemical group 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 235000002639 sodium chloride Nutrition 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000010828 elution Methods 0.000 description 11
- 230000005484 gravity Effects 0.000 description 11
- 239000012265 solid product Substances 0.000 description 11
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 10
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 238000001953 recrystallisation Methods 0.000 description 10
- 239000011347 resin Substances 0.000 description 10
- 229920005989 resin Polymers 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 229910020889 NaBH3 Inorganic materials 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 229910052786 argon Inorganic materials 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 230000002829 reductive effect Effects 0.000 description 9
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 8
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- 238000001704 evaporation Methods 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- 229940097042 glucuronate Drugs 0.000 description 8
- 239000012074 organic phase Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- LJBWEZVYRBKOCI-UHFFFAOYSA-N 2,4,6-triaminoquinazoline Chemical compound N1=C(N)N=C(N)C2=CC(N)=CC=C21 LJBWEZVYRBKOCI-UHFFFAOYSA-N 0.000 description 7
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 7
- QFFVPLLCYGOFPU-UHFFFAOYSA-N barium chromate Chemical compound [Ba+2].[O-][Cr]([O-])(=O)=O QFFVPLLCYGOFPU-UHFFFAOYSA-N 0.000 description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 7
- 229910000019 calcium carbonate Inorganic materials 0.000 description 7
- 239000003054 catalyst Substances 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- OZRNSSUDZOLUSN-LBPRGKRZSA-N dihydrofolic acid Chemical compound N=1C=2C(=O)NC(N)=NC=2NCC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OZRNSSUDZOLUSN-LBPRGKRZSA-N 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical group 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000011159 matrix material Substances 0.000 description 7
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical compound C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- 230000007062 hydrolysis Effects 0.000 description 6
- 238000006460 hydrolysis reaction Methods 0.000 description 6
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- OXJSGJWNRYFYGA-UHFFFAOYSA-N 2-amino-5-(methylamino)benzonitrile Chemical compound CNC1=CC=C(N)C(C#N)=C1 OXJSGJWNRYFYGA-UHFFFAOYSA-N 0.000 description 5
- HLCPWBZNUKCSBN-UHFFFAOYSA-N 2-aminobenzonitrile Chemical compound NC1=CC=CC=C1C#N HLCPWBZNUKCSBN-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 229910052763 palladium Inorganic materials 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000012264 purified product Substances 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- RHZGFTNGGQAHIQ-UHFFFAOYSA-N 1-(4-methoxyphenyl)sulfonyl-4-methylbenzene Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=CC=C(C)C=C1 RHZGFTNGGQAHIQ-UHFFFAOYSA-N 0.000 description 4
- UOUHDIZYOCFQKG-UHFFFAOYSA-N 2-(4-methylphenyl)sulfonylnaphthalene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 UOUHDIZYOCFQKG-UHFFFAOYSA-N 0.000 description 4
- WZWIQYMTQZCSKI-UHFFFAOYSA-N 4-cyanobenzaldehyde Chemical compound O=CC1=CC=C(C#N)C=C1 WZWIQYMTQZCSKI-UHFFFAOYSA-N 0.000 description 4
- YZMJNZRTRWPJFY-UHFFFAOYSA-N 6-nitroquinazoline-2,4-diamine Chemical compound C1=C([N+]([O-])=O)C=CC2=NC(N)=NC(N)=C21 YZMJNZRTRWPJFY-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical class [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 150000001879 copper Chemical class 0.000 description 4
- 239000006260 foam Substances 0.000 description 4
- 229960000304 folic acid Drugs 0.000 description 4
- 229940097043 glucuronic acid Drugs 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 4
- 150000004678 hydrides Chemical class 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 125000002950 monocyclic group Chemical group 0.000 description 4
- XUZLXCQFXTZASF-UHFFFAOYSA-N nitro(phenyl)methanol Chemical compound [O-][N+](=O)C(O)C1=CC=CC=C1 XUZLXCQFXTZASF-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000010802 sludge Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 229960001099 trimetrexate Drugs 0.000 description 4
- NOYPYLRCIDNJJB-UHFFFAOYSA-N trimetrexate Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C(=C3C(N)=NC(N)=NC3=CC=2)C)=C1 NOYPYLRCIDNJJB-UHFFFAOYSA-N 0.000 description 4
- RMQDOUFFCRQDMD-UHFFFAOYSA-N 1-(4-methylphenyl)sulfonylnaphthalene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC=CC2=CC=CC=C12 RMQDOUFFCRQDMD-UHFFFAOYSA-N 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 102000006933 Hydroxymethyl and Formyl Transferases Human genes 0.000 description 3
- 108010072462 Hydroxymethyl and Formyl Transferases Proteins 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical class [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 239000007868 Raney catalyst Substances 0.000 description 3
- 229910000564 Raney nickel Inorganic materials 0.000 description 3
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 125000005219 aminonitrile group Chemical group 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 3
- 239000012535 impurity Substances 0.000 description 3
- 230000002101 lytic effect Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 150000007522 mineralic acids Chemical class 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005460 tetrahydrofolate Substances 0.000 description 3
- 229940035024 thioglycerol Drugs 0.000 description 3
- 238000010626 work up procedure Methods 0.000 description 3
- MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 description 2
- HBKDLRFVBAEDCF-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-(bromomethyl)benzene Chemical compound C1=CC(CBr)=CC=C1S(=O)(=O)C1=CC=CC=C1 HBKDLRFVBAEDCF-UHFFFAOYSA-N 0.000 description 2
- GIFMLLQPKAYJLZ-UHFFFAOYSA-N 1-[4-(benzenesulfonyl)phenyl]-n-methylmethanamine Chemical compound C1=CC(CNC)=CC=C1S(=O)(=O)C1=CC=CC=C1 GIFMLLQPKAYJLZ-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 description 2
- QEBYEVQKHRUYPE-UHFFFAOYSA-N 2-(2-chlorophenyl)-5-[(1-methylpyrazol-3-yl)methyl]-4-[[methyl(pyridin-3-ylmethyl)amino]methyl]-1h-pyrazolo[4,3-c]pyridine-3,6-dione Chemical compound C1=CN(C)N=C1CN1C(=O)C=C2NN(C=3C(=CC=CC=3)Cl)C(=O)C2=C1CN(C)CC1=CC=CN=C1 QEBYEVQKHRUYPE-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- SYNLKYAZHAVAOV-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]sulfonylnaphthalene Chemical compound C1=CC(CBr)=CC=C1S(=O)(=O)C1=CC=C(C=CC=C2)C2=C1 SYNLKYAZHAVAOV-UHFFFAOYSA-N 0.000 description 2
- AHVICFDTMNVUER-UHFFFAOYSA-N 2-amino-5-[2-[4-(4-fluorophenyl)sulfonylphenyl]ethylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C=CC(F)=CC=2)C=C1 AHVICFDTMNVUER-UHFFFAOYSA-N 0.000 description 2
- SZEOCEPPITZUDP-UHFFFAOYSA-N 2-amino-5-[2-[4-(benzenesulfonyl)phenyl]ethylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1 SZEOCEPPITZUDP-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 description 2
- NWPNXBQSRGKSJB-UHFFFAOYSA-N 2-methylbenzonitrile Chemical compound CC1=CC=CC=C1C#N NWPNXBQSRGKSJB-UHFFFAOYSA-N 0.000 description 2
- SWBDKCMOLSUXRH-UHFFFAOYSA-N 2-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC=CC=C1C#N SWBDKCMOLSUXRH-UHFFFAOYSA-N 0.000 description 2
- NBTTYMBZXDHFCP-UHFFFAOYSA-N 4-(4-methylphenyl)sulfonylmorpholine Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N1CCOCC1 NBTTYMBZXDHFCP-UHFFFAOYSA-N 0.000 description 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 2
- DLMAPFAEDQLTBP-UHFFFAOYSA-N 4-methylsulfanyl-6-nitroquinazolin-2-amine Chemical compound C1=C([N+]([O-])=O)C=C2C(SC)=NC(N)=NC2=C1 DLMAPFAEDQLTBP-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 description 2
- OTCCUFYXJRZFJQ-UHFFFAOYSA-N 5-[2-(4-naphthalen-1-ylsulfonylphenyl)ethylamino]-2-nitrobenzonitrile Chemical compound C1=C(C#N)C([N+](=O)[O-])=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C3=CC=CC=C3C=CC=2)C=C1 OTCCUFYXJRZFJQ-UHFFFAOYSA-N 0.000 description 2
- VJXSSYDSOJBUAV-UHFFFAOYSA-N 6-(2,5-dimethoxy-benzyl)-5-methyl-pyrido[2,3-d]pyrimidine-2,4-diamine Chemical compound COC1=CC=C(OC)C(CC=2C(=C3C(N)=NC(N)=NC3=NC=2)C)=C1 VJXSSYDSOJBUAV-UHFFFAOYSA-N 0.000 description 2
- QLYYXUDSKVMCAH-UHFFFAOYSA-N 6-n-[2-[4-(benzenesulfonyl)phenyl]ethyl]-4-methylsulfanylquinazoline-2,6-diamine Chemical compound C1=C2C(SC)=NC(N)=NC2=CC=C1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 QLYYXUDSKVMCAH-UHFFFAOYSA-N 0.000 description 2
- IRBAWVGZNJIROV-SFHVURJKSA-N 9-(2-cyclopropylethynyl)-2-[[(2s)-1,4-dioxan-2-yl]methoxy]-6,7-dihydropyrimido[6,1-a]isoquinolin-4-one Chemical compound C1=C2C3=CC=C(C#CC4CC4)C=C3CCN2C(=O)N=C1OC[C@@H]1COCCO1 IRBAWVGZNJIROV-SFHVURJKSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- LTKHPMDRMUCUEB-IBGZPJMESA-N CB3717 Chemical compound C=1C=C2NC(N)=NC(=O)C2=CC=1CN(CC#C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 LTKHPMDRMUCUEB-IBGZPJMESA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 229910004373 HOAc Inorganic materials 0.000 description 2
- 101000653005 Homo sapiens Thromboxane-A synthase Proteins 0.000 description 2
- 101000809797 Homo sapiens Thymidylate synthase Proteins 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- LVDRREOUMKACNJ-BKMJKUGQSA-N N-[(2R,3S)-2-(4-chlorophenyl)-1-(1,4-dimethyl-2-oxoquinolin-7-yl)-6-oxopiperidin-3-yl]-2-methylpropane-1-sulfonamide Chemical compound CC(C)CS(=O)(=O)N[C@H]1CCC(=O)N([C@@H]1c1ccc(Cl)cc1)c1ccc2c(C)cc(=O)n(C)c2c1 LVDRREOUMKACNJ-BKMJKUGQSA-N 0.000 description 2
- POFVJRKJJBFPII-UHFFFAOYSA-N N-cyclopentyl-5-[2-[[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]amino]-5-fluoropyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1(CCCC1)NC=1SC(=C(N=1)C)C1=NC(=NC=C1F)NC1=NC=C(C=C1)CN1CCN(CC1)CC POFVJRKJJBFPII-UHFFFAOYSA-N 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 2
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- RYTLGWCJESCDMY-UHFFFAOYSA-N carbamimidoyl chloride Chemical compound NC(Cl)=N RYTLGWCJESCDMY-UHFFFAOYSA-N 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229940126208 compound 22 Drugs 0.000 description 2
- GYOZYWVXFNDGLU-XLPZGREQSA-N dTMP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)C1 GYOZYWVXFNDGLU-XLPZGREQSA-N 0.000 description 2
- JSRLJPSBLDHEIO-SHYZEUOFSA-N dUMP Chemical compound O1[C@H](COP(O)(O)=O)[C@@H](O)C[C@@H]1N1C(=O)NC(=O)C=C1 JSRLJPSBLDHEIO-SHYZEUOFSA-N 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 150000002224 folic acids Chemical class 0.000 description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000010907 mechanical stirring Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 238000004452 microanalysis Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- WZKOKGOAHBIPCI-UHFFFAOYSA-N n,n,4-trimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(C)C=C1 WZKOKGOAHBIPCI-UHFFFAOYSA-N 0.000 description 2
- VQSRKMNBWMHJKY-YTEVENLXSA-N n-[3-[(4ar,7as)-2-amino-6-(5-fluoropyrimidin-2-yl)-4,4a,5,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-methoxypyrazine-2-carboxamide Chemical compound C1=NC(OC)=CN=C1C(=O)NC1=CC=C(F)C([C@@]23[C@@H](CN(C2)C=2N=CC(F)=CN=2)CSC(N)=N3)=C1 VQSRKMNBWMHJKY-YTEVENLXSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 2
- 229950001030 piritrexim Drugs 0.000 description 2
- 229920000137 polyphosphoric acid Polymers 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 235000011118 potassium hydroxide Nutrition 0.000 description 2
- 238000012746 preparative thin layer chromatography Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000011369 resultant mixture Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- NOQPJZHAGRHCFW-UHFFFAOYSA-N (2,3,4,5,6-pentafluorophenyl) formate Chemical compound FC1=C(F)C(F)=C(OC=O)C(F)=C1F NOQPJZHAGRHCFW-UHFFFAOYSA-N 0.000 description 1
- VFVAGPWBFWJBMN-YUMQZZPRSA-N (3s,8as)-3-(2-methylsulfanylethyl)-2,3,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1[C@H](CCSC)NC(=O)[C@@H]2CCCN21 VFVAGPWBFWJBMN-YUMQZZPRSA-N 0.000 description 1
- QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 description 1
- LBBZMVQJOYHHJJ-UHFFFAOYSA-N 1-(5-bromothiophen-2-yl)sulfonyl-4-phenylpiperazine Chemical compound S1C(Br)=CC=C1S(=O)(=O)N1CCN(C=2C=CC=CC=2)CC1 LBBZMVQJOYHHJJ-UHFFFAOYSA-N 0.000 description 1
- MONGUDQJUIVFPI-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-fluorobenzene Chemical compound C1=CC(F)=CC=C1S(=O)(=O)C1=CC=CC=C1 MONGUDQJUIVFPI-UHFFFAOYSA-N 0.000 description 1
- YBRXHRWLEFCFEG-UHFFFAOYSA-N 1-(benzenesulfonyl)-4-methylbenzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC=CC=C1 YBRXHRWLEFCFEG-UHFFFAOYSA-N 0.000 description 1
- IFQMMZNPCQOKIS-UHFFFAOYSA-N 1-(bromomethyl)-4-(4-methoxyphenyl)sulfonylbenzene Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C1=CC=C(CBr)C=C1 IFQMMZNPCQOKIS-UHFFFAOYSA-N 0.000 description 1
- BOCHNTFSFIEKPM-UHFFFAOYSA-N 1-(bromomethyl)-4-(4-nitrophenyl)sulfonylbenzene Chemical compound C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)C1=CC=C(CBr)C=C1 BOCHNTFSFIEKPM-UHFFFAOYSA-N 0.000 description 1
- VZKCACNGULLCGO-UHFFFAOYSA-N 1-[4-(4-methoxyphenyl)sulfonylphenyl]-n-methylmethanamine Chemical compound C1=CC(CNC)=CC=C1S(=O)(=O)C1=CC=C(OC)C=C1 VZKCACNGULLCGO-UHFFFAOYSA-N 0.000 description 1
- VEHNPSGIIAAQGG-UHFFFAOYSA-N 1-[4-(bromomethyl)phenyl]sulfonylnaphthalene Chemical compound C1=CC(CBr)=CC=C1S(=O)(=O)C1=CC=CC2=CC=CC=C12 VEHNPSGIIAAQGG-UHFFFAOYSA-N 0.000 description 1
- ZOZNCAMOIPYYIK-UHFFFAOYSA-N 1-aminoethylideneazanium;acetate Chemical compound CC(N)=N.CC(O)=O ZOZNCAMOIPYYIK-UHFFFAOYSA-N 0.000 description 1
- WFQDTOYDVUWQMS-UHFFFAOYSA-N 1-fluoro-4-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=C(F)C=C1 WFQDTOYDVUWQMS-UHFFFAOYSA-N 0.000 description 1
- RVHDYDZMDKCAOE-UHFFFAOYSA-N 1-methyl-4-(4-nitrophenyl)sulfonylbenzene Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 RVHDYDZMDKCAOE-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- AVRPFRMDMNDIDH-UHFFFAOYSA-N 1h-quinazolin-2-one Chemical class C1=CC=CC2=NC(O)=NC=C21 AVRPFRMDMNDIDH-UHFFFAOYSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- TUYWOTKNXZPUNL-UHFFFAOYSA-N 2-[(2-bromobenzoyl)amino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide Chemical compound S1C=2CCCCC=2C(C(=O)N)=C1NC(=O)C1=CC=CC=C1Br TUYWOTKNXZPUNL-UHFFFAOYSA-N 0.000 description 1
- RCQFFJOWCZZZJU-UHFFFAOYSA-N 2-[4-(bromomethyl)phenyl]sulfonylmorpholine Chemical compound C1=CC(CBr)=CC=C1S(=O)(=O)C1OCCNC1 RCQFFJOWCZZZJU-UHFFFAOYSA-N 0.000 description 1
- VHVLADONSCFURW-UHFFFAOYSA-N 2-amino-5-(ethylamino)benzonitrile Chemical compound CCNC1=CC=C(N)C(C#N)=C1 VHVLADONSCFURW-UHFFFAOYSA-N 0.000 description 1
- KOQLMIWXSDWMCX-UHFFFAOYSA-N 2-amino-5-[2-(4-naphthalen-2-ylsulfonylphenyl)ethylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)C=C1 KOQLMIWXSDWMCX-UHFFFAOYSA-N 0.000 description 1
- OFFMOHIORPTKDZ-UHFFFAOYSA-N 2-amino-5-[2-[4-(4-hydroxyphenyl)sulfonylphenyl]ethylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C=CC(O)=CC=2)C=C1 OFFMOHIORPTKDZ-UHFFFAOYSA-N 0.000 description 1
- CXSZISFGODOTEW-UHFFFAOYSA-N 2-amino-5-[2-[4-(4-methoxyphenyl)sulfonylphenyl]ethylamino]benzonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C(C=C1)=CC=C1CCNC1=CC=C(N)C(C#N)=C1 CXSZISFGODOTEW-UHFFFAOYSA-N 0.000 description 1
- KTVQRDOUFRECTF-UHFFFAOYSA-N 2-amino-5-[2-[4-(4-nitrophenyl)sulfonylphenyl]ethylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCC1=CC=C(S(=O)(=O)C=2C=CC(=CC=2)[N+]([O-])=O)C=C1 KTVQRDOUFRECTF-UHFFFAOYSA-N 0.000 description 1
- CYANTMZEQFPFHS-UHFFFAOYSA-N 2-amino-5-[3-[4-(benzenesulfonyl)phenyl]propylamino]benzonitrile Chemical compound C1=C(C#N)C(N)=CC=C1NCCCC1=CC=C(S(=O)(=O)C=2C=CC=CC=2)C=C1 CYANTMZEQFPFHS-UHFFFAOYSA-N 0.000 description 1
- OZLMBXPYRDASTP-UHFFFAOYSA-N 2-amino-5-methylbenzonitrile Chemical compound CC1=CC=C(N)C(C#N)=C1 OZLMBXPYRDASTP-UHFFFAOYSA-N 0.000 description 1
- LJJAAYBESUEDHX-UHFFFAOYSA-N 2-amino-6-[2-[4-(benzenesulfonyl)phenyl]ethylamino]-1h-quinazolin-4-one Chemical compound C=1C=C2NC(N)=NC(=O)C2=CC=1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 LJJAAYBESUEDHX-UHFFFAOYSA-N 0.000 description 1
- AFQWWNVKKIMPGC-UHFFFAOYSA-N 2-amino-6-nitro-1h-quinazolin-4-one Chemical compound [O-][N+](=O)C1=CC=C2NC(N)=NC(=O)C2=C1 AFQWWNVKKIMPGC-UHFFFAOYSA-N 0.000 description 1
- DXPQTHAFYUTZRR-UHFFFAOYSA-N 2-methylquinazoline Chemical compound C1=CC=CC2=NC(C)=NC=C21 DXPQTHAFYUTZRR-UHFFFAOYSA-N 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- ZKUYSJHXBFFGPU-UHFFFAOYSA-N 2516-95-2 Chemical compound OC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O ZKUYSJHXBFFGPU-UHFFFAOYSA-N 0.000 description 1
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 1
- BOHCMQZJWOGWTA-UHFFFAOYSA-N 3-methylbenzonitrile Chemical compound CC1=CC=CC(C#N)=C1 BOHCMQZJWOGWTA-UHFFFAOYSA-N 0.000 description 1
- PVDXGXYFQAGKPL-UHFFFAOYSA-N 4-(benzenesulfonyl)benzenethiol Chemical compound C1=CC(S)=CC=C1S(=O)(=O)C1=CC=CC=C1 PVDXGXYFQAGKPL-UHFFFAOYSA-N 0.000 description 1
- KTFSQBCKLKHZRU-UHFFFAOYSA-N 4-(bromomethyl)-n,n-dimethylbenzenesulfonamide Chemical compound CN(C)S(=O)(=O)C1=CC=C(CBr)C=C1 KTFSQBCKLKHZRU-UHFFFAOYSA-N 0.000 description 1
- UMLFTCYAQPPZER-UHFFFAOYSA-N 4-(bromomethyl)benzonitrile Chemical compound BrCC1=CC=C(C#N)C=C1 UMLFTCYAQPPZER-UHFFFAOYSA-N 0.000 description 1
- ZDHKVKPZQKYREU-UHFFFAOYSA-N 4-(chloromethyl)pyridine;hydron;chloride Chemical compound Cl.ClCC1=CC=NC=C1 ZDHKVKPZQKYREU-UHFFFAOYSA-N 0.000 description 1
- GIFDOXTYKIJOIH-UHFFFAOYSA-N 4-[2-[(2,4-diaminoquinazolin-6-yl)amino]ethyl]benzonitrile Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1NCCC1=CC=C(C#N)C=C1 GIFDOXTYKIJOIH-UHFFFAOYSA-N 0.000 description 1
- PLYTVTIWUZXQGH-UHFFFAOYSA-N 4-[[(2,4-diaminoquinazolin-6-yl)amino]methyl]benzonitrile Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1NCC1=CC=C(C#N)C=C1 PLYTVTIWUZXQGH-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- POXFXTSTVWDWIR-UHFFFAOYSA-N 4-iodobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(I)C=C1 POXFXTSTVWDWIR-UHFFFAOYSA-N 0.000 description 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
- HPSGCGRMYILEKS-UHFFFAOYSA-N 4-methylsulfanylquinazoline-2,6-diamine Chemical compound C1=C(N)C=C2C(SC)=NC(N)=NC2=C1 HPSGCGRMYILEKS-UHFFFAOYSA-N 0.000 description 1
- WOYVDJWBZMQHJU-UHFFFAOYSA-N 4-n-methyl-6-nitroquinazoline-2,4-diamine Chemical compound C1=C([N+]([O-])=O)C=C2C(NC)=NC(N)=NC2=C1 WOYVDJWBZMQHJU-UHFFFAOYSA-N 0.000 description 1
- IFNAWCNNVMVCEU-UHFFFAOYSA-N 4-n-methylquinazoline-2,4,6-triamine Chemical compound C1=C(N)C=C2C(NC)=NC(N)=NC2=C1 IFNAWCNNVMVCEU-UHFFFAOYSA-N 0.000 description 1
- 125000004937 4H-carbazolyl group Chemical group C=1(C=CCC2=C3C=CC=CC3=NC12)* 0.000 description 1
- 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
- BTJYWJVLRHNVAP-UHFFFAOYSA-N 5,6-dimethylbenzimidazol-1-amine Chemical compound C1=C(C)C(C)=CC2=C1N(N)C=N2 BTJYWJVLRHNVAP-UHFFFAOYSA-N 0.000 description 1
- SNQIDHLNUZDDQF-UHFFFAOYSA-N 5-(ethylamino)-2-nitrobenzonitrile Chemical compound CCNC1=CC=C([N+]([O-])=O)C(C#N)=C1 SNQIDHLNUZDDQF-UHFFFAOYSA-N 0.000 description 1
- ODZZVUCAPOLFTL-UHFFFAOYSA-N 5-(methylamino)-2-nitrobenzonitrile Chemical compound CNC1=CC=C([N+]([O-])=O)C(C#N)=C1 ODZZVUCAPOLFTL-UHFFFAOYSA-N 0.000 description 1
- DJKKNLNNCNCBRY-UHFFFAOYSA-N 5-[2-[4-(3-bromoindol-1-yl)sulfonylphenyl]ethylamino]-2-nitrobenzonitrile Chemical compound C1=C(C#N)C([N+](=O)[O-])=CC=C1NCCC1=CC=C(S(=O)(=O)N2C3=CC=CC=C3C(Br)=C2)C=C1 DJKKNLNNCNCBRY-UHFFFAOYSA-N 0.000 description 1
- FYMNLZVKOASUSO-UHFFFAOYSA-N 5-[2-[4-(4-methoxyphenyl)sulfonylphenyl]ethylamino]-2-nitrobenzonitrile Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)C(C=C1)=CC=C1CCNC1=CC=C([N+]([O-])=O)C(C#N)=C1 FYMNLZVKOASUSO-UHFFFAOYSA-N 0.000 description 1
- PHFJBWUNWQSFKM-UHFFFAOYSA-N 5-[methyl-[(4-morpholin-4-ylsulfonylphenyl)methyl]amino]-2-nitrobenzonitrile Chemical compound C=1C=C([N+]([O-])=O)C(C#N)=CC=1N(C)CC(C=C1)=CC=C1S(=O)(=O)N1CCOCC1 PHFJBWUNWQSFKM-UHFFFAOYSA-N 0.000 description 1
- USQNWFKYQFQGLB-UHFFFAOYSA-N 5-methyl-2-nitrobenzonitrile Chemical compound CC1=CC=C([N+]([O-])=O)C(C#N)=C1 USQNWFKYQFQGLB-UHFFFAOYSA-N 0.000 description 1
- IDRNKSCTPZAYSQ-UHFFFAOYSA-N 6-n,6-n-dimethylquinazoline-2,4,6-triamine Chemical compound N1=C(N)N=C(N)C2=CC(N(C)C)=CC=C21 IDRNKSCTPZAYSQ-UHFFFAOYSA-N 0.000 description 1
- YQUDBWSRAXEZMO-UHFFFAOYSA-N 6-n-[2-[4-(4-azidophenyl)sulfonylphenyl]ethyl]quinazoline-2,4,6-triamine Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=C(N=[N+]=[N-])C=C1 YQUDBWSRAXEZMO-UHFFFAOYSA-N 0.000 description 1
- GKKVNQHTIZKLJQ-UHFFFAOYSA-N 6-n-[2-[4-(4-fluorophenyl)sulfonylphenyl]ethyl]quinazoline-2,4,6-triamine Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=C(F)C=C1 GKKVNQHTIZKLJQ-UHFFFAOYSA-N 0.000 description 1
- XIKZQLDVNCMRKJ-UHFFFAOYSA-N 6-n-[2-[4-(benzenesulfonyl)phenyl]ethyl]-2-n-methylquinazoline-2,4,6-triamine Chemical compound C1=CC2=NC(NC)=NC(N)=C2C=C1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 XIKZQLDVNCMRKJ-UHFFFAOYSA-N 0.000 description 1
- MRDZIWHCPRLWCD-UHFFFAOYSA-N 6-n-[2-[4-(benzenesulfonyl)phenyl]ethyl]quinazoline-2,4,6-triamine Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1NCCC(C=C1)=CC=C1S(=O)(=O)C1=CC=CC=C1 MRDZIWHCPRLWCD-UHFFFAOYSA-N 0.000 description 1
- WWUBAHSWMPFIQZ-UHFFFAOYSA-N 6-nitro-1h-3,1-benzoxazine-2,4-dione Chemical compound N1C(=O)OC(=O)C2=CC([N+](=O)[O-])=CC=C21 WWUBAHSWMPFIQZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 241000400611 Eucalyptus deanei Species 0.000 description 1
- 244000166102 Eucalyptus leucoxylon Species 0.000 description 1
- 235000004694 Eucalyptus leucoxylon Nutrition 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BOPGDPNILDQYTO-NNYOXOHSSA-L NADH(2-) Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP([O-])(=O)OP([O-])(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-L 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000002262 Schiff base Substances 0.000 description 1
- 150000004753 Schiff bases Chemical class 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229910020446 SiO2/5 Inorganic materials 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- PJSFRIWCGOHTNF-UHFFFAOYSA-N Sulphormetoxin Chemical compound COC1=NC=NC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1OC PJSFRIWCGOHTNF-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 241001061127 Thione Species 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 229940122149 Thymidylate synthase inhibitor Drugs 0.000 description 1
- IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- XMXYHWSZLDVJQY-UHFFFAOYSA-N [benzenesulfonyl(bromo)methyl]benzene Chemical compound C=1C=CC=CC=1S(=O)(=O)C(Br)C1=CC=CC=C1 XMXYHWSZLDVJQY-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- XPOLVIIHTDKJRY-UHFFFAOYSA-N acetic acid;methanimidamide Chemical compound NC=N.CC(O)=O XPOLVIIHTDKJRY-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
- 125000005157 alkyl carboxy group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- YNNGZCVDIREDDK-UHFFFAOYSA-N aminocarbamodithioic acid Chemical compound NNC(S)=S YNNGZCVDIREDDK-UHFFFAOYSA-N 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000001365 aminolytic effect Effects 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 150000003931 anilides Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 229940045687 antimetabolites folic acid analogs Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 150000001500 aryl chlorides Chemical class 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000001743 benzylic group Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- PASHVRUKOFIRIK-UHFFFAOYSA-L calcium sulfate dihydrate Chemical compound O.O.[Ca+2].[O-]S([O-])(=O)=O PASHVRUKOFIRIK-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- OTVRWKSAXMIQRR-UHFFFAOYSA-N chembl1372111 Chemical compound OC1=CC=CC=C1C1=NNC(C(F)(F)F)=C1 OTVRWKSAXMIQRR-UHFFFAOYSA-N 0.000 description 1
- 238000000451 chemical ionisation Methods 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 1
- 229910052593 corundum Inorganic materials 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 150000001923 cyclic compounds Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- IUNMPGNGSSIWFP-UHFFFAOYSA-N dimethylaminopropylamine Chemical compound CN(C)CCCN IUNMPGNGSSIWFP-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 239000012259 ether extract Substances 0.000 description 1
- 239000002024 ethyl acetate extract Substances 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000012966 insertion method Methods 0.000 description 1
- 230000002687 intercalation Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- UIPPTRJAYGYCNR-UHFFFAOYSA-N methyl 2-amino-5-[2-[4-(benzenesulfonyl)phenyl]ethylamino]benzoate Chemical compound C1=C(N)C(C(=O)OC)=CC(NCCC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC=CC=2)=C1 UIPPTRJAYGYCNR-UHFFFAOYSA-N 0.000 description 1
- QMTPUASIPMRCOK-UHFFFAOYSA-N methyl 5-[2-[4-(benzenesulfonyl)phenyl]ethylamino]-2-nitrobenzoate Chemical compound C1=C([N+]([O-])=O)C(C(=O)OC)=CC(NCCC=2C=CC(=CC=2)S(=O)(=O)C=2C=CC=CC=2)=C1 QMTPUASIPMRCOK-UHFFFAOYSA-N 0.000 description 1
- JGBJHRKCUKTQOE-UHFFFAOYSA-N methyl 5-chloro-2-nitrobenzoate Chemical compound COC(=O)C1=CC(Cl)=CC=C1[N+]([O-])=O JGBJHRKCUKTQOE-UHFFFAOYSA-N 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- ANXGDXZTHLYXNE-UHFFFAOYSA-N n-methyl-1-(4-morpholin-4-ylsulfonylphenyl)methanamine Chemical compound C1=CC(CNC)=CC=C1S(=O)(=O)N1CCOCC1 ANXGDXZTHLYXNE-UHFFFAOYSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000002560 nitrile group Chemical group 0.000 description 1
- 230000006959 non-competitive inhibition Effects 0.000 description 1
- AKPLHCDWDRPJGD-UHFFFAOYSA-N nordazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)CN=C1C1=CC=CC=C1 AKPLHCDWDRPJGD-UHFFFAOYSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 239000013618 particulate matter Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 125000005327 perimidinyl group Chemical group N1C(=NC2=CC=CC3=CC=CC1=C23)* 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
- 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- QJFMCHRSDOLMHA-UHFFFAOYSA-N phenylmethanamine;hydrobromide Chemical compound Br.NCC1=CC=CC=C1 QJFMCHRSDOLMHA-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- KFZUDNZQQCWGKF-UHFFFAOYSA-M sodium;4-methylbenzenesulfinate Chemical compound [Na+].CC1=CC=C(S([O-])=O)C=C1 KFZUDNZQQCWGKF-UHFFFAOYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- SEEPANYCNGTZFQ-UHFFFAOYSA-N sulfadiazine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=NC=CC=N1 SEEPANYCNGTZFQ-UHFFFAOYSA-N 0.000 description 1
- 229960004306 sulfadiazine Drugs 0.000 description 1
- 229960004673 sulfadoxine Drugs 0.000 description 1
- 229960005404 sulfamethoxazole Drugs 0.000 description 1
- GPTONYMQFTZPKC-UHFFFAOYSA-N sulfamethoxydiazine Chemical compound N1=CC(OC)=CN=C1NS(=O)(=O)C1=CC=C(N)C=C1 GPTONYMQFTZPKC-UHFFFAOYSA-N 0.000 description 1
- 229960002229 sulfametoxydiazine Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
- 150000003571 thiolactams Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 239000003734 thymidylate synthase inhibitor Substances 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910001845 yogo sapphire Inorganic materials 0.000 description 1
- 125000004933 β-carbolinyl group Chemical group C1(=NC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- the present invention relates to certain quinazoline compounds which are capable of inhibiting folate metabolic pathways, to pharmaceutical compositions containing these compounds, and to the use of these compounds to inhibit folate metabolic pathways, including all effects derived from the inhibition of folate metabolic pathways.
- Effects derived from the inhibition of folate metabolic pathways include the inhibition of the growth and proliferation of the cells of higher organisms and microorganisms, such as bacteria, yeasts and fungi. Such effects may include the inhibition of the enzymes thymidylate synthase or dihydrofolate reductase, or both.
- a process for preparing the antifolate quinazoline compounds according to the present invention is also
- a large class of antiproliferative agents includes antimetabolite compounds.
- a particular subclass of antiproliferative agents includes antimetabolite compounds.
- antimetabolites known as antifolates or antifols are
- antifolates closely resemble the structure of folic acid and incorporate the characteristic p-benzoyl glutamate moiety of folic acid. Because the glutamate moiety of folic acid takes on a double negative charge at physiological pH, this
- MTX methotrexate
- MTX has been used widely in the treatment of human neoplastic diseases, such as malignant diseases.
- the cytotoxic action of MTX is ascribed generally to its inhibition of the enzyme dihydrofolate reductase
- DHFR a key enzyme which maintains the pools of one- carbon carrying tetrahydrofolates.
- MTX a key enzyme which maintains the pools of one- carbon carrying tetrahydrofolates.
- DHFR DHFR
- piritrexim and trimetrexate both of which lack the glutamate moiety
- these two agents penetrate the cell wall by passive diffusion and, thus, can affect both normal tumor cells and those resistant because of a transport defect.
- These compounds have been found active even against tumor cells having an MTX transport defect. Because they are more soluble than MTX in organic solvents and in lipids, they have been termed lipophilic DHFR inhibitors.
- trimetrexate may be active against opportunistic infections which occur in patients infected with HIV (human
- TS thymidylate synthase
- dUMP 2'-deoxyuridylate
- dTMP 2'-deoxythymidylate
- the present invention relates to novel quinazoline compounds which are capable of inhibiting folate metabolic pathways, to pharmaceutical compositions containing these compounds, and to the use of these compounds to inhibit folate metabolic pathways, including all effects derived from the inhibition of folate metabolic pathways.
- Effects derived from the inhibition of folate metabolic pathways include the inhibition of the growth and proliferation of the cells of higher organisms and of microorganisms, such as bacteria, yeasts and fungi. Such effects may include the inhibition of the enzymes thymidylate synthase or dihydrofolate reductase, or both.
- the present invention relates to quinazoline compounds having the formula I
- R 1 and R 2 which may be the same or different, represent electron-donating substituents;
- R 3 represents a -S-CH 2 - group, a -CH 2 -S- group or a
- R 5 is hydrogen or a lower alkyl
- R 4 represents a substituted or unsubstituted aryl or heteroaryl group
- R 4 does not represent (a) an unsubstituted phenyl; (b) an unsubstituted naphthyl; (c) a substituted phenyl selected from the group consisting of mono-, di- or tri-(lower alkyl)phenyl, mono- or di- halophenyl, hydroxyphenyl, mono-, di- or tri-(lower alkoxy)phenyl, carboxyphenyl, carb-(lower alkoxy)phenyl, nitrophenyl, aminophenyl, mono- or di-(lower alkyl) aminophenyl, and acetamidophenyl; (d) a phenyl substituted in the para-position with any of the following groups: -CO-NHR b where R b is such that NH 2 -R b is an amino acid, a poly(amino acid), a lower alkyl ester of an
- the language “capable of inhibiting folate metabolic pathways” refers to the ability of a
- such a compound may effectively inhibit the growth and proliferation of the cells of higher organisms and
- quinazoline compounds according to the present invention are either capable of inhibiting the enzyme thymidylate synthase or capable of inhibiting the enzyme dihydrofolate reductase, or both.
- thymidylate synthase refers to a compound having a TS inhibition constant K i of less than or equal to about 10 -4 M.
- TS K i values in the range of less than about 10 -5 M, preferably less than about 10 -6 M, more preferably less tftan about 10 -9 M and most preferably less than about 10 -12 M.
- dihydrofolate reductase refers to a compound having a DHFR inhibition constant K i of less than or equal to about 10 -6 M.
- DHFR K i values in the range of less than about 10 -8 M, preferably less than about 10 -10 M, more preferably less than about 10 -12 M and most preferably less than about 10 -13 M.
- substituents R 1 and R 2 of formula I above include -NH 2 , -NH-
- lower alkyl (lower alkyl), -NHOH, -NHNH 2 , -S-(lower alkyl) and -NR 6 R 7 , wherein R 6 and R 7 represent substituted or unsubstituted lower alkyl groups.
- the language “lower alkyl”, “lower alkoxy” and the like refers to groups having one to six carbon atoms.
- “lower alkyl” may refer to methyl, ethyl, n-propyl, isopropyl and the like.
- at least one of R 1 and R 2 is -NH 2 . More
- both R 1 and R 2 are -NH 2 .
- substituent R 3 of formula I may be a -S-CH 2 - group, a -CH 2 -S- group or a -N(R 5 )-CH 2 - group, wherein R 5 is hydrogen or a lower alkyl.
- R 3 is a
- R 5 is preferably a methyl or ethyl group.
- R 4 substituent of formula I can be any one of a large number of ring compounds selected from the group consisting of substituted or unsubstituted aryl and
- heteroaryl rings examples include phenyl, 1,2,3,4-tetrahydro-naphthyl, naphthyl, phenanthryl, anthryl and the like.
- aryl ring groups include phenyl, 1,2,3,4-tetrahydro-naphthyl, naphthyl, phenanthryl, anthryl and the like.
- typical heteroaryl rings include 5-membered monocyclic ring groups such as thienyl, pyrrolyl, 2H-pyrrolyl, imidazolyl,
- R 1 and R 2 both represent -NH 2 , R 4 , does not represent (a) an unsubstituted phenyl; (b) an
- a substituted phenyl selected from the group consisting of mono-, di- or tri-(lower alkyl)phenyl, mono- or di- halophenyl, hydroxyphenyl, mono-, di- or tri-(lower alkoxy)phenyl, carboxyphenyl, carb-(lower alkoxy)phenyl, nitrophenyl, aminophenyl, mono- or di-(lower alkyl) aminophenyl, and acetamidophenyl; (d) a phenyl substituted in the para-position with any of the following groups: -CO-NHR b where R b is such that NH 2 -R b is an amino acid, a poly(amino acid), a lower alkyl ester of an amino acid, or a lower alkyl ester of a poly(amino acid); (e) a substituted naphthyl selected from the group consisting of
- R 1 and R 2 are -NH 2
- R 4 is preferably a monocyclic or bicyclic aryl or heteroaryl ring. More preferably, R 4 is a phenyl, naphthyl or monocyclic or bicyclic heteroaryl ring, and most preferably, R 4 is phenyl.
- R 4 may be unsubstituted, or R 4 may be substituted with one or more of a wide variety of electron-donating and electron-withdrawing substituents.
- electron-withdrawing refers to groups such as -NO 2 , -CN, carboxy, halogen, SO 2 R 8 , wherein R 8 is as defined hereunder, and the like.
- electron-donating refers to groups such as -NH 2 , -NH- (lower alkyl), -NHOH, -NHNH 2 , -S-(lower alkyl) and -NR 6 R 7 , wherein
- R 6 and R 7 represent lower alkyl groups, and the like.
- quinazoline compounds according to the claimed invention may demonstrate activity against serine
- hydroxymethyltransferase glycineamineribotide transformylase and aminoimidazolecarboxamideribotide transformylase.
- Typical substituents for R 4 include halogen, hydroxy, lower alkoxy, lower alkyl, hydroxyalkyl, fluoroalkyl, amino,
- R 4 is substituted with at least one electron-withdrawing group such as -NO 2 , -CN, carboxy, halogen, -SO 2 R 8 , wherein R 8 is as defined hereunder, and the like. More preferably, R 4 is substituted with a -CN or -SO 2 group. Even more preferably, R 4 is substituted by a
- R 8 represents an aryl or heteroaryl group, such as phenyl, naphthyl, indole, or morpholino.
- R 4 is substituted in the para-position (i.e., the
- R 8 When R 4 is a phenyl group substituted by a -SO 2 -R 8 group wherein R 8 is an aryl or heteroaryl group, R 8 may also be substituted with a variety of substituents, such as those discussed above for R 4 .
- R 8 is phenyl substituted by hydroxy, lower alkoxy, amino, (lower alkyl)-amino, (lower alkyl)-thio, nitro, carboxy, halogen and the like.
- R 4 Particularly preferred structures for R 4 include:
- a preferred class of compounds according to the present invention includes those compounds according to formula I, wherein at least one of R 1 and R 2 is -NH 2 , R 3 is -N(lower alkyl)CH 2 -, preferably -N(CH 3 )CH 2 -and R 4 is phenyl
- R 8 is an aryl or heteroaryl group as discussed above.
- R 8 is unsubstituted phenyl or phenyl substituted by hydroxy, lower alkoxy, amino, (lower alkyl)-amino, (lower alkyl)-thio, nitro, carboxy, halogen and the like.
- a particularly preferred class of compounds according to the present invention includes those compounds according to formula I, wherein both R 1 and R 2 are -N H2 , R 3 is -N(CH 3 )CH 2 - or -N(CH 2 CH 3 )CH 2 -, and R 4 is phenyl substituted at the para position by -SO 2 -R 8 , wherein R 4 is an aryl or heteroaryl group as discussed above. More preferably, R 8 is
- Another preferred class of compounds according to the present invention includes those compounds according to formula I, wherein at least one of R 1 and R 2 is -NH 2 , R 3 is - S-CH 2 - or -CH 2 -S-, and R 4 is phenyl substituted at the para position by -SO 2 -R 8 , wherein R 8 is an aryl or heteroaryl group as discussed above. More preferably, R 8 is
- R 1 and R 2 are -NH 2 ,
- Another preferred class of compounds according to the present invention includes those compounds according to formula I, wherein at least one of R 1 and R 2 is -NH 2 , R 3 is -
- R 4 is a cyanophenyl group. More preferably, both R 1 and R 2 are -NH 2 .
- Particularly preferred compounds according to the present invention include:
- Another aspect of the present invention relates to processes of making the antifolate quinazoline compounds of formula I.
- a preferred process according to the present invention for making the antifolate quinazoline compounds of formula I, wherein R 1 -R 4 have the same meanings as described previously, comprises the steps of:
- step (2) reacting the product of step (1) with 5-chloro-2- nitrobenzontrile to form a nitro-containing intermediate
- step (3) (4) reacting the product of step (3) with a cyclization reagent.
- the first step of reacting the compound L - CH 2 - R 4 with a (lower alkyl) -amine compound can be carried out under widely varying conditions, but is preferably carried out with an excess of the amine, and if not, then in the presence of a base, typically at a temperature varying from about 0°C to about 100°C, preferably from about room temperature to about
- Step (2) may also be carried out under widely varying conditions, but is typically carried out in a solvent, preferably DMSO, and in the presence of a base, such as CaCO 3 , at a temperature varying from about room temperature to about 189°C, preferably from about 60°C to about 150°C, and most preferably from about 80°C to about 120°C.
- a solvent preferably DMSO
- a base such as CaCO 3
- Step (3) the reducing step, can be performed under widely varying reduction conditions, but is preferably carried out in an organic solvent such as ethanol, methanol, ethyl acetate, tetrahydrofuran or acetic acid, in the
- a reducing agent such as a KBH 4 ./CuCl or hydrogen gas
- a vapor pressure of one atmosphere or higher under a vapor pressure of one atmosphere or higher, and at a temperature varying from about room temperature to about 100°C, preferably from about room temperature to about 60°C, and most preferably at about room temperature.
- a reduction catalyst such as Raney nickel, palladium on
- charcoal, palladium on barium sulfate and the like may also be used where appropriate.
- step (4) cyclization of the product of step (3) may be induced by reacting the product of step (3) with a
- cyclization reagent such as chlorformamidine hydrochloride, cyanamide together with pyridine hydrochloride, S,S- dimethyldithiocarbiminium iodide, thiourea, and the like. If thiourea is used as the cyclization reagent, compounds according to the present invention may be obtained by further reacting the product of step (4) with NaH, followed by iodomethane. Step (4) may be carried out under widely varying conditions, but is typically carried out in the presence of an acid at a temperature varying from about room temperature to about 200°C, preferably from about room temperature to about 180°C, and most preferably from about 150°C to about 165°C.
- Another process of making the antifolate quinazoline compounds of formula I, wherein R 1 -R 4 have the same meanings as discussed previously, comprises the steps of:
- L is a leaving group, for example, a halogen atom such as Br, Cl, F and I, the lower alkyl amino is, for example, methylamino,
- R 4 has the same meaning as described above for formula I;
- step (2) reacting the product of step (1) with a cyclization reagent.
- the first step of reacting the compound L - CH 2 - R 4 with a 2-amino-5-(lower alkyl amino)benzonitrile compound can be carried out under widely varying conditions, but is typically carried out in the presence of a base at a
- 150°C preferably from about 45°C to about 110°C, and most preferably at about 60°C.
- step (2) the cyclization step, the reagent used to induce cyclization may be a wide variety of compounds such as chlorformamidine hydrochloride, cyanamide together with pyridine hydrochloride, S,S-dimethyldithiocarbiminium iodide, thiourea, and the like. If thiourea is used, compounds according to the present invention may be obtained by further reacting the product of step (2) with NaH, followed by iodomethane. Step (2) may be carried out under widely varying conditions, but is typically carried out in the presence of an acid at a temperature varying from about room temperature to about 200°C, preferably from about room temperature to about 180°C, and most preferably from about
- Another process according to the present invention for making the compounds of formula I, wherein R 1 -R 4 have the same meaning as discussed previously, comprises the steps of:
- step (2) lysing the trifluoroacetyl group of the product of step (1); and (3) reacting the product of step (2) with a cyclization reagent.
- Step (1) can be carried out under widely varying
- a base at a temperature varying from about 0°C to about 100°C, preferably from about room temperature to about 60°C, and most preferably at about room temperature.
- Step (2) which is a deprotection step, can be performed under widely varying lytic conditions, but is preferably carried out with methanolic ammonia at a temperature varying from about 0°C to about 100°C, preferably from about room temperature to about 60°C, and most preferably at about room temperature.
- lytic conditions includes, but is not limited to, hydrolytic, alcoholytic, ammonolytic and aminolytic conditions.
- step (3) the cyclization step
- the reagent used to induce cyclization may be a wide variety of compounds such as chlorformamidine hydrochloride, cyanamide together with pyridine hydrochloride, S,S-dimethyldithiocarbiminium iodide, thiourea, and the like. If thiourea is used, compounds according to the present invention may be obtained by further reacting the product of step (3) with NaH, followed by iodomethane.
- Step (4) may be carried out under widely varying
- an acid at a temperature varying from about room temperature to about 200°C, preferably from about room temperature to about 180°C, and most preferably from about 150°C to about
- This reaction may be carried out under widely varying conditions, but is typically carried out at a temperature varying from about room temperature to about 150°C,
- CH 2 -S, and R 4 has the same meaning as discussed previously, comprises the steps of:
- R 3 is -S-CH 2 - or -CH 2 -S-, with a reducing agent to give a compound having the formula
- R 3 is -S-CH 2 - or -CH 2 -S-;
- R 3 is -S-CH 2 - or -CH 2 -S-;
- step (3) (4) reacting the product of step (3) with a cyclization reagent.
- concomitant hydrolysis of the nitrile group may be carried out under widely varying conditions which employ a reducing agent, but is preferably carried out (i) with stannous chloride dihydrate in ethyl acetate or in ethanol at a temperature varying from about 0°C to about 77°C, preferably from about room temperature to about 77°C, and most
- Step (2) may also be carried out under widely varying conditions, but is typically carried out with an excess of the reagent in the presence of a base in an inert solvent at a temperature varying from about 0°C to about 100°C,
- Step (3) which is a deprotection step, can be performed under widely varying lytic conditions, but is preferably carried out with methanolic ammonia at a temperature varying from about 0°C to about 100°C, preferably from about room temperature to about 60°C, and most preferably at about room temperature.
- the reagent used to induce cyclization may be a wide variety of compounds such as chlorformamidine hydrochloride, cyanamide together with pyridine hydrochloride, S,S-dimethyldithiocarbiminium iodide, thiourea, and the like. If thiourea is used, compounds according to the present invention may be obtained by further reacting the product of step (4) with NaH, followed by iodomethane.
- a suitable protecting group for a ring nitrogen, such as may be included in a heteroaryl group is for example, a pivaloyloxymethyl group, which may be removed by hydrolysis with a base such as sodium hydroxide; a tert-butyloxycarbonyl group, which may be removed by hydrolysis with an acid, such as hydrochloric acid or trifluoroacetic acid, or with a base such as tetra-n-butylammonium fluoride ("TBAF”) or lithium hydroxide; or a 2-(trimethylsilyl)ethoxymethyl group, which may be removed by TBAF or with an acid such as hydrochloric acid.
- a base such as sodium hydroxide
- a tert-butyloxycarbonyl group which may be removed by hydrolysis with an acid, such as hydrochloric acid or trifluoroacetic acid, or with a base such as tetra-n-butylammonium fluoride ("TBAF") or lithium hydroxide
- a suitable protecting group for a hydroxyl group is, for example, an esterifying group such as an acetyl or benzoyl group, which may be removed by hydrolysis with a base such as sodium hydroxide.
- the protecting group may be, for example, an alpha- arylalkyl group such as a benzyl group, which may be removed by hydrogenation in the presence of a catalyst such as palladium on charcoal or Raney nickel.
- protecting group for a hydroxyl group is a group such as tbutyldiphenylsilyl (-Si-t-Bu-Ph 2 ), which may be removed by treatment with TBAF.
- a suitable protecting group for a mercapto group is, for example, an esterifying group such as an acetyl group, which may be removed by hydrolysis with a base such as sodium hydroxide.
- a suitable protecting group for an amino group may be, for example, an alkylcarbonyl group such as an acetyl group (CH 3 CO-), which may be removed by treatment with an aqueous inorganic acid such as nitric, sulfuric or hydrochloric acid.
- an alkylcarbonyl group such as an acetyl group (CH 3 CO-)
- an aqueous inorganic acid such as nitric, sulfuric or hydrochloric acid.
- alkoxycarbonyl group such as a methoxycarbonyl or a tert- butyloxycarbonyl group. These groups may be removed by treatment with an organic acid such as trifluoroacetic acid.
- a suitable protecting group for a primary amino group is, for example, an acetyl group, which may be removed by treatment with an aqueous inorganic acid such as nitric, sulfuric, or hydrochloric acid, or a phthaloyl group, which may be removed by treatment with an alkylamine such as dimethylaminopropylamine or with hydrazine.
- a suitable protecting group for a carboxy group may be an esterifying group, for example, a methyl or an ethyl group, which may be removed by hydrolysis with a base such as sodium hydroxide.
- Another useful protecting group is a tert- butyl group, which may be removed by treatment with an organic acid such as trifluoro-acetic acid.
- Preferred protecting groups include an esterifying group, an alpha-arylalkyl group, an alkylcarboxyl group, a substituted or unsubstituted alkoxycarbonyl group, a
- oxyether-type group such as methoxymethyl or 2- (trimethylsilyl)ethoxymethyl, or a silicon group such as a tert-butyldiphenylsilyl group.
- antifolate quinazoline compounds of the present invention which may be employed in the pharmaceutical compositions according to the present invention, include all of those compounds described above, as well as
- acid addition salts of the compounds of the invention containing a basic group are formed, where appropriate, with strong or moderately strong organic or inorganic acids in the presence of a basic amine by methods known in the art.
- Exemplary of the acid addition salts which are included in this invention are maleate, fumarate, lactate, oxalate, ethanesulfonate, ethanesulfonate, benzenesulfonate, tartrate, glucuronate citrate, sulfate, phosphate and nitrate salts.
- Pharmaceutically acceptable base addition salts of compounds of the invention containing an acidic group are prepared by known methods from organic and inorganic bases , and include nontoxic alkali metal and alkaline earth bases, for example, calcium, sodium and potassium hydroxides; ammonium hydroxides; and nontoxic organic bases such as triethylamine, butylamine, piperazine and tri(hydroxymethyl)-methylamine.
- nontoxic alkali metal and alkaline earth bases for example, calcium, sodium and potassium hydroxides; ammonium hydroxides; and nontoxic organic bases such as triethylamine, butylamine, piperazine and tri(hydroxymethyl)-methylamine.
- the compounds of the invention possess antiproliferative activity, a property which may express itself in the form of antitumor activity.
- a compound of the invention may be active per se or it may be a pro-drug that is converted in vivo to an active compound.
- Preferred compounds of the invention are active in inhibiting the growth of the L1210 cell line, a mouse leukemia cell line which can be grown in tissue culture.
- Such compounds of the invention are also active in inhibiting the growth of bacteria such as Escherichia coli gram negative bacteria which can be grown in culture.
- invention may also be active inhibiting the growth of bacteria.
- antifolate compounds according to the present invention may be incorporated into convenient dosage forms such as capsules, tablets, or inje-ctable preparations.
- Solid or liquid pharmaceutically acceptable carriers may be
- Solid carriers include starch, lactose, calcium sulfate dihydrate, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate and stearic acid.
- Liquid carriers include syrup, peanut oil, olive oil, saline and water.
- the carrier or diluent may include any prolonged release materiel, such as glyceryl monostearate or glyceryl distearate, alone or with wax.
- the preparation may be in the form of a syrup, elixir, emulsion, soft gelatin capsule, sterile injectable liquid (e.g. solution), such as an ampoule, or an aqueous or nonaqueous liquid suspension.
- the pharmaceutical preparations are made following conventional techniques of a pharmaceutical chemist involving steps such as mixing, granulating and compressing, when necessary for tablet forms; or mixing, filling and dissolving the ingredients, as appropriate, to give the desired products for oral, parenteral, topical, intravaginal, intranasal, intrabronchial, intraocular, intraaural and rectal
- composition of the invention may further comprise one or more other compounds which are antitumor agents, such as a mitotic inhibitors (e.g., vinblastine), alkylating agents (e.g., cis-platin, carboplatin and cyclophosphamide), other DHFR inhibitors (e.g., methotrexate, piritrexim and trimetrexate), other TS inhibitors, antimetabolites (e.g., 5- fluorouracil and cytosine arabinoside), intercalating a mitotic inhibitors (e.g., vinblastine), alkylating agents (e.g., cis-platin, carboplatin and cyclophosphamide), other DHFR inhibitors (e.g., methotrexate, piritrexim and trimetrexate), other TS inhibitors, antimetabolites (e.g., 5- fluorouracil and cytosine arabinoside), intercalating
- a mitotic inhibitors
- antibiotics e.g., adriamycin and bleomycin
- enzymes e.g., asparaginase
- topoisomerase inhibitors e.g., etoposide
- biological response modifiers e.g., interferon
- composition of the invention may also comprise one or more other compounds, including antibacterial, antifungal, antiparasitic, antiviral, antipsoriatic and anticoccidial agents.
- antibacterial agents include, for example, sulfonamide such as sulfamethoxazole, sulfadiazine,
- DHFR inhibitors such as
- trimethoprim bromodiaprim or trimetrexate; penicillins;
- cephalosporins aminoglycosides
- bacteriostatic inhibitors of protein synthesis the quinolonecarboxylic acids and their fused isothiazolo analogs.
- Another aspect of the invention relates to a therapeutic process of inhibiting the folate metabolic pathways, which process comprises administering to a host, such as a
- vertebrate host for example, a mammal or bird, an amount effective to inhibit the folate metabolic pathways of a compound according to the present invention.
- the compounds of the invention are particularly useful in the treatment of mammalian hosts, such as human hosts, and in the treatment of avian hosts.
- any of the antifolate compounds described above, or pharmaceutically acceptable salts thereof, may be employed in the therapeutic process of the invention.
- the compounds of the invention may be administered in the form of a pharmaceutically acceptable composition comprising a diluent or carrier, such as those described above.
- Doses of the compounds preferably include pharmaceutical dosage units comprising an efficacious quantity of active compound.
- an efficacious quantity is meant a quantity sufficient to inhibit the folate metabolic pathways and derive the
- An exemplary daily dosage unit for a vertebrate host comprises an amount of up to about 1 gram of active compound per kilogram of the host, preferably one half of a gram, more preferably 100
- milligrams and most preferably about 50 milligrams per kilogram of the host.
- the selected dose may be administered to a warmblooded animal or mammal, for example a human patient, in need of treatment mediated by folate metabolic pathways inhibition by any known method of administration, including topically (e.g. as an ointment or cream), orally, rectally (e.g., as a suppository), parentally, by injection or continuously by infusion, intravaginally, intranasally, intrabronchially, intraaurally or intraocularly.
- topically e.g. as an ointment or cream
- rectally e.g., as a suppository
- parentally by injection or continuously by infusion, intravaginally, intranasally, intrabronchially, intraaurally or intraocularly.
- the antifolate compounds according to the present invention may be further characterized as producing any one or more of an antiproliferative effect, an antibacterial effect, an antiparasitic effect, an antiviral effect, an antipsoriatic effect, an antiprotozoal effect, an
- the compounds are especially useful in producing an antitumor effect in a vertebrate host harboring a tumor.
- Proton magnetic resonance spectra were determined using a General Electric QE-300 spectrometer operating at a field strength of 300 MHz. Chemical shifts are reported in parts per million ( ⁇ ) downfield from tetramethylsilane as an internal standard and peak multiplicities are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; dq, doublet of quartets; t, triplet; br s, broad singlet; br d, broad doublet; br m, broad multiplet; br, broad signal; m, multiplet. El mass spectra were determined using a VG 7070E- HF high resolution mass spectrometer using the direct
- N,N-Dimethylformamide (DMF) was dried over activated (250°C) 3- ⁇ molecular sieves; N,N-dimethylacetamide (DMA, Aldrich Gold Label grade), and hexamethylphosphoramide (HMPA, Aldrich) were similarly dried.
- Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl under nitrogen.
- AIBN is 2,2'-azobis (2-methylpropionitrile).
- Diglyme is bis(2-methoxyethyl) ether.
- Ether refers to diethyl ether.
- Petrol refers to petroleum ether of bp 36-53°C. Flash
- TLC plates were aluminium oxide 60F 254 (Merck Art 5731), and flash column packing was basic alumina (Merck Art 1076). Extracts were dried over Na 2 SO 4 or MgSO 4 . Melting points were determined on a Mel-Temp apparatus and are corrected.
- 2,4-Diamino-6-nitroquinazoline (3) was prepared from 2,4-diaminoquinazoline by a published method (ibid, method a) conducted on a 0.19 mol scale. Yield>90%.
- 2,4,6-Triaminoquinazoline (4) was prepared by a slightly modified procedure of the above reference. A suspension of 2,4-diamiono-6-nitroquinazoline (25 g) in DMF (900 mL) containing 10% Pd:C (5 g) was stirred for 22 h at 25°C and atmospheric pressure. The mixture was filtered through celite, and the filtrate was evaporated under reduced
- 2-Amino-4-hydroxy-6-nitroquinazoline (8 ) was prepared from 5-nitroisatoic anhydride (7 ) by a published method [J . B . Hynes, Y.C.S. Yang, J.G. McGill, S.J. Harmon and W.L.
- the gum was dissolved in glacial HOAc (200 mL) to give a solution which was then brought to pH 6 with 1N NaOH.
- the resulting crude solid was filtered off, washed with water and redissolved in boiling HOAc (800 mL).
- the solution was charcoal treated and brought to pH 5 with 2N NaOH.
- the resulting yellow-orange, flocculent solid was filtered off, washed with water, and dried in a desiccator (12.41 g, 51%).
- the resulting solution was heated at 70-100°C for 2 h 15 min, cooled to room temperature, carbon treated, and filtered.
- the liquid layer when brought to pH 9 with NH 4 OH, contained no desired product by TLC (SiO 2 /5% Et 3 N, 10% MeOH, 85% CH 2 Cl 2 ), and was thus discarded.
- the resin was treated with a mixture of DMF (100 mL), and Et 3 N (13 mL, 88 mmol) and gently warmed to give a dark brown solution which was treated with charcoal and filtered. The charcoal was rinsed with MeOH (30 ml), and the combined filtrate was cooled. It was then poured onto ice (500 g) containing 1 N NaOH (100 mL) with stirring. The resulting crude orange-colored product was collected, washed with H 2 O (2 x 100 mL) and dried in a desiccator. It was coated onto SiO 2 (30 g) from DMF and flash chromatographed on SiO 2 (400 g) using 5% Et 3 N, 10% MeOH, 85% CH 2 Cl 2 as the eluant.
- N-(p-toluenesulfonyl)morpholine 55, 10.00 g, 41 mmol
- CCl 4 CCl 4
- N- bromosuccinimide 8.85 g, 49 mmol 1.2 eq
- the organic phase was extracted with H 2 O (400 mL), dried, and evaporated to give the crude product as a beige solid which was used without purification (14 g). It contained about 50% desired monobromide by TLC (SiO 2 -50% EtOAc in hexane).
- chlorformamidine hydrochloride (0.08 g, 0.7 mmol, 0.5 eq) was added. At 1 h 40 min, the mixture was cooled, and the diglyme layer was decanted from the brown resin which had formed. The resin was dissolved in DMF (4.5 mL), treated with Et 3 N (0.97 mL, 7 mmol, 5 eq), poured into H 2 O (50 mL), and extracted with EtOAc (25 mL). Saturated brine (50 mL) was added to the aqueous layer and it was extracted once more with EtOAc (25 mL). The extracts were combined, dried, and evaporated to give an orange-colored oil which was
- the resin was dissolved in EtOH (30 mL), treated with N,N-diisopropylethylamine (0.69 mL, 4 mmol, 4 eq), poured into saturated brine (175 mL), and extracted with EtOAc (2 x 30 mL). The combined extracts were dried and coated onto basic alumina (2 g). Chromatography on basic alumina (40 g) with 10% MeOH in CH 2 Cl 2 as eluant gave the product as an orange-colored solid (40 mg, 9.2%), mp 272- 274°C.
- Method B A mixture of 2-amino-5-(N-(4-((4- fluorophenyl) sulfonyl)benzyl)methylamino)benzonitrile (1.98 g, 5 mmol), pyridine hydrochloride (3.47 g, 30 mmol, 6 eq), and cyanamide (0.84 g, 20 mmol, 4 eq), was heated at 165°C to give a brown melt which spontaneously resolidified after 5 min. The mixture was immediately cooled, and the solid was broken up and triturated with boiling EtOH (25 mL), treated give a brown melt which spontaneously resolidified after 5 min.
- methylamino)benzonitrile (23.3 g, 54.6 mmol) and diglyme (100 mL) were stirred at about 70°C for 20 min.
- Chlorformamidine hydrochloride (7.5 g, 65.5 mmol, 1.2 eq) was then added in portions during 15 min.
- the resulting mixture was heated at 150°C for 1.5 h with occasional manual stirring with a glass rod.
- the cooled mixture was triturated with Et2 ⁇ (2 x 100 mL).
- the ether was decanted, and the remaining solid was dissolved in a warm water mixture of DMF (260 mL) and Et 3 N (26 mL). The resulting solution was treated with charcoal and filtered.
- 4-((2-Naphthyl)sulfonyl)toluene (88) was prepared by the method of B. Graybill [J. Org. Chem. 32, 2931, (1967)]: 2- Naphthalene sulfonic acid, 70% (120 g, 0.40 mol), toluene (80 mL, 69 g, 0.75 mol, 1.3 eq.), and polyphosphoric acid (1 Kg) were placed in a flanged reaction kettle with mechanical stirring and heated at 80°C for 16 h. The mixture was removed from the heat and poured into ice-water (2 L) and stirred until it attained ambient temperature.
- Methyl dithiocarbamate was prepared by a published method [J. von Braun, Berichte Deutschen Chemischen
- Trifluoroacetic anhydride (0.59 mL, 4.16 mmol, 1.leq) was added dropwise during 15 min to a stirred solution of 2- amino-5-methylbenzonitrile (111, 500 mg, 3.78 mmol) and Et 3 N (0.58 mL, 4.2 mmol, 1.leq) in CH 2 Cl 2 (5 mL) in an ice bath. The resulting mixture was then stirred at 25°C for 30 min. It was treated with 1N HCl (5 mL) to give pH ⁇ 2.
- the toluene 112 (13.11 g, 57.5 mmol) was dissolved in warm benzene (50 mL). H 2 O (25 mL) was added, and the mixture was brought to reflux. A 200 watt light was shone on it, and a solution of bromine (3.26 mL. 63.2 mmol, 1.leq) in benzene (25 mL) was added dropwise during 45 min at a rate that maintained an orange-red color. The organic layer was separated, dried, and evaporated to give a pale yellow, feathery, crystalline solid which was dried in vacuo over P 2 O 5 (13.92 g) It was used without further purification.
- cyanamide (44 mg, 1.05 mmol. 4 eq) was homogenized with a glass rod in a 25 mL round bottom flask, which was then immersed in a 165°C oil bath for 5 min. A melt resulted which was cooled to room temperature, whereupon it became a sludge.
- EtOH (5 mL) was added, and the mixture was heated to boiling while being worked with a glass rod.
- Et 3 N (0.29 mL, 2.10 mmol, 8 eq) was then added, and the mixture boiled further; a yellow precipitate formed. The mixture was cooled and put on ice.
- Each diaminoquinazoline was prepared by heating a
- Glucuronic acid (32.8 g, 169 mmol, 5 eq) was dissolved in boiling MeOH (1 L), and to it was added 2,4-diamino-6-(N- (4-(phenylsulfonyl)benzyl)methylamino)quinazoline (22, 14.2 g, 33.8 mmol).
- the resulting solution was immediately hot filtered to remove traces of entrained matter, and the filtrate was boiled for 10 min to reduce its volume to about 820 mL, whereupon the first trace of product, a fluffy solid, started to appear.
- the mixture was removed from heat, cooled slowly, and kept for 10 days at 25°C to fully crystallize.
- Glucuronate salts were prepared by dissolving glucuronic acid (5 mol eq) in boiling MeOH to give a solution to which was added the free base ( 1 mol eq). The resulting hot solution was immediately filtered to remove trace particulate matter, and the filtrate was allowed to cool to room
- the glucuronate 130 was prepared by dissolving the glucuronic acid (5 eq) in boiling MeOH followed by
- the glucuronate 134 was precipitated with Et 2 O (450 mL), collected, and washed with Et 2 O (250 mL).
- the filtrate was evaporated down to a volume of 200 mL, and Et 2 O (200 mL) was added to precipitate a second crop which was collected and washed with Et 2 O (150 mL).
- Et 2 O 200 mL
- the second filtrate deposited a third crop which was filtered off and washed with Et 2 O (100 mL).
- Thymidylate synthase activity was measured using a modification of the tritium release method of Lomax and
- dUMP 2'-deoxyuridine 5'- monophosphate
- coli TS and 60 ng for human TS).
- Assays of human TS also contained 1-5 ⁇ g/ mL bovine serum albumin to stabilize the protein. Reactions were initiated by the addition of enzyme and were carried out for 5 minutes at 24°C, and then quenched by the addition of charcoal (15 mg in 0.1 mL H 2 O). The quenched samples were centrifuged at 10,000 rpm for 12-15 min at 40°C to remove unreacted dUMP which had bound to the charcoal, and 0.1 mL of the supernatant was counted by liquid scintillation in the presence of 5 mL ecolume to determine the release of tritium label from the 5-position of the dUMP.
- DHFR inhibition constants were determined using purified human recombinant enzyme at 25°C. All reaction mixtures contained 50 ⁇ M Tris at pH 7.5, 60 ⁇ M NADPH (nicotinamide adenine dinucleotide, reduced form).
- Reaction mixtures containing DHFR, were preincubated for 2 min in the presence of inhibitor before initiation by
- DHF concentration of DHF was 50 ⁇ M(s).
- a time course was monitored for each inhibitor concentration to determine the maximum steady state reaction rate after
- Rate measurements for at least eight inhibitor concentrations were used in each K i determination.
- K i slope K i , app / (1 + s/K m )
- lymphoblastic leukemia line of T-cell origin ATCC CCL 119
- a thymidine kinase-deficient human colon adenocarcinoma GC 3 /M TK- (supplied by Drs. P.J. and J.A. Houghton, St. Jude Childrens Research Hospital, Memphis, TN).
- Cell lines were maintained in RPMI 1640 medium containing 5% (L1210, CCRF- CEM) or 10% (GC 3 /M TK-) heat-inactivated fetal bovine serum without antibiotics.
- IC 50 values were determined in 150 ⁇ L microcultures each containing 1500 (L1210) or 10,000 (CCRF-CEM, GCg/M TK-) cells established in 96 well plates in growth medium
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
On décrit certains composés de quinazoline pouvant inhiber les voies métaboliques des folates, des compositions pharmaceutiques les contenant, et leur utilisation dans l'inhibition des voies métaboliques des folates, notamment tous les effets dérivés de l'inhibition des voies métaboliques des folates. Les effets dérivés de l'inhibition des voies métaboliques des folates sont notamment l'inhibition de la croissance et de la prolifération des cellules des organismes supérieurs et des microorganismes, par exemple les bactéries, les levures et les champignons. Ces effets comprennent éventuellement l'inhibition des enzymes thymidylate-synthase et/ou dihydrofolate-réductase. On a également prévu un procédé de préparation de ces composés anti-folates de quinazoline.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81227491A | 1991-12-20 | 1991-12-20 | |
US07/812,274 | 1991-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993013079A1 true WO1993013079A1 (fr) | 1993-07-08 |
Family
ID=25209084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1992/010730 WO1993013079A1 (fr) | 1991-12-20 | 1992-12-16 | Quinazolines anti-folates |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU3276793A (fr) |
WO (1) | WO1993013079A1 (fr) |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0797980A1 (fr) * | 1996-03-29 | 1997-10-01 | Wella Aktiengesellschaft | Composition de teinture d'oxydation des fibres kératiniques comprenant un 2,5-diaminobenzonitrile ainsi que dérivés de 2,5-diaminobenzonitrile |
WO2000071160A1 (fr) * | 1999-05-24 | 2000-11-30 | Sankyo Company, Limited | Compositions medicinales contenant un anticorps anti-fas |
WO2001004087A1 (fr) * | 1999-07-13 | 2001-01-18 | Eli Lilly And Company Limited | Derives benzylamine substitues de sulfonamides et leur utilisation comme medicaments |
JP2007532625A (ja) * | 2004-04-13 | 2007-11-15 | セファロン インコーポレイティド | チオ置換アリールメタンスルフィニル誘導体 |
US7829708B2 (en) | 2004-09-08 | 2010-11-09 | Chelsea Therapeutics, Inc. | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
US20110009369A1 (en) * | 2008-02-05 | 2011-01-13 | British Columbia Cancer Agency Branch | Anti-influenza compounds |
US7951812B2 (en) | 2007-01-19 | 2011-05-31 | Chelsea Therapeutics, Inc. | Substituted pyrrolo[2,3-d]pyrimidines as antifolates |
WO2011121309A1 (fr) | 2010-03-31 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dérivés phénylsulfonyle et leur utilisation comme antagonistes de l'histamine h3 |
US8530653B2 (en) | 2009-11-06 | 2013-09-10 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
US8658652B2 (en) | 2010-12-07 | 2014-02-25 | Chelsea Therapeutics, Inc. | Antifolate combinations |
WO2021078995A1 (fr) | 2019-10-25 | 2021-04-29 | Umc Utrecht Holding B.V. | Composé et test de blocage de la synthèse de polypeptides sélectif |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857530A (en) * | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
EP0373891A2 (fr) * | 1988-12-15 | 1990-06-20 | Imperial Chemical Industries Plc | Agents antitumoraux |
-
1992
- 1992-12-16 WO PCT/US1992/010730 patent/WO1993013079A1/fr active Application Filing
- 1992-12-16 AU AU32767/93A patent/AU3276793A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4857530A (en) * | 1987-11-03 | 1989-08-15 | Warner-Lambert Company | Substituted quinazolinones as anticancer agents |
EP0373891A2 (fr) * | 1988-12-15 | 1990-06-20 | Imperial Chemical Industries Plc | Agents antitumoraux |
Non-Patent Citations (14)
Title |
---|
CHEMICAL ABSTRACTS, vol. 102, no. 15, 15 April 1985, Columbus, Ohio, US; abstract no. 131989b, ZHANG 'Sudies on antimalarials.' page 626 ;column 1 ; * |
CHEMICAL ABSTRACTS, vol. 110, no. 5, 30 January 1989, Columbus, Ohio, US; abstract no. 33336g, YAN 'Antitumor effects of 66 quinazolines and pyrimidines in vitro.' * |
CHEMICAL ABSTRACTS, vol. 111, no. 11, 11 September 1989, Columbus, Ohio, US; abstract no. 97177j, ZHOU 'Synthesis and antimalarial and antitumor activities of 2,4-diamino-6-(ben zylmethylamino)quinazolines.' page 738 ;column 2 ; * |
CHEMICAL ABSTRACTS, vol. 115, no. 5, 5 August 1991, Columbus, Ohio, US; abstract no. 50236v, MARSHAM 'Quinazoline antifolate thymidylate synthase inhibitors' page 907 ;column 2 ; * |
CHEMICAL ABSTRACTS, vol. 98, no. 21, 23 May 1983, Columbus, Ohio, US; abstract no. 179317g, LI 'Studies on antimalarials.' page 654 ;column 2 ; * |
J.MED.CHEM. vol. 15, no. 11, 1972, pages 1138 - 46 ELSLAGER ET AL 'Folate Antagonists' Tables I and II: many compounds only excluded by provisos a)-c). * |
J.MED.CHEM. vol. 15, no. 8, 1972, pages 812 - 826 DAVOLL ET AL 'Folate Antagonists' Formula Vi, examples 49-53,77 * |
J.MED.CHEM. vol. 17, no. 9, 1974, pages 943 - 47 RICHTER ET AL 'Inhibition of Mammalian Dihydrofolate Reductase by selected 2,4-Diaminoquinazolines and Related Compounds.' Table I: many compounds only excluded by the provisos. * |
J.MED.CHEM. vol. 20, no. 1, 1977, pages 96 - 102 HANSCH ET AL 'Quantitative Structure-Activity Relationships of Antimalarial and Dihydrofolate Reductase Inhibition by Quinazolines and 5-Substituted Benzyl-2,4,-diaminopyridines.' Table 1, i.a. examples 17,22-24,31,32 * |
J.MED.CHEM. vol. 21, no. 7, 1978, pages 639 - 43 ELSLAGER ET AL 'Folate Antagonists.' Ia-Ic only excluded by provisos. * |
J.MED.CHEM. vol. 22, no. 5, 1979, pages 483 - 91 CHEN ET AL 'Multivirate Analysis and Quantitative Structure-Activity Relationships.' Table I; i.a. examples 41-48 * |
J.MED.CHEM. vol. 24, no. 2, 1981, pages 127 - 140 ELSLAGER ET AL 'Synthesis and Antimalarial Effects of N2-Aryl-N4-Ä(dialkylamino)alkylÜ- and N4-A ryl-N2-Ä(dialkylamino)alkyl]-2,4-quinazoli nediamines.' VIIa, example 73 * |
J.MED.CHEM. vol. 31, no. 2, 1988, pages 449 - 454 HYNES ET AL 'Inhibition of Murine Thymidylate Synthase and Human Dihydrofolate Reductase by 5,8-Dideaza analagues of Folic Acid and Aminopterin.' Examples 2a-c, 3a-e,4a-e * |
J.MED.CHEM. vol. 32, no. 7, 1989, pages 1559 - 1565 PATIL ET AL 'Inhibition of Mammalian Folylpolyglutamate Synthetase and Human Dihydrofolate Reductase by5,8-Dideaza Analogues of Folic Acid and Aminopterin Bearing a Terminal L-Ornithine.' 2a,3a * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0797980A1 (fr) * | 1996-03-29 | 1997-10-01 | Wella Aktiengesellschaft | Composition de teinture d'oxydation des fibres kératiniques comprenant un 2,5-diaminobenzonitrile ainsi que dérivés de 2,5-diaminobenzonitrile |
US5865856A (en) * | 1996-03-29 | 1999-02-02 | Wella Aktiengesellschaft | 2, 5-diaminobenzonitrile compounds and oxidation hair dye compositions containing same |
WO2000071160A1 (fr) * | 1999-05-24 | 2000-11-30 | Sankyo Company, Limited | Compositions medicinales contenant un anticorps anti-fas |
US6746673B2 (en) | 1999-05-24 | 2004-06-08 | Sankyo Company, Limited | Pharmaceutical compositions containing anti-Fas antibody |
WO2001004087A1 (fr) * | 1999-07-13 | 2001-01-18 | Eli Lilly And Company Limited | Derives benzylamine substitues de sulfonamides et leur utilisation comme medicaments |
JP2007532625A (ja) * | 2004-04-13 | 2007-11-15 | セファロン インコーポレイティド | チオ置換アリールメタンスルフィニル誘導体 |
US7829708B2 (en) | 2004-09-08 | 2010-11-09 | Chelsea Therapeutics, Inc. | Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
US7951812B2 (en) | 2007-01-19 | 2011-05-31 | Chelsea Therapeutics, Inc. | Substituted pyrrolo[2,3-d]pyrimidines as antifolates |
US20110009369A1 (en) * | 2008-02-05 | 2011-01-13 | British Columbia Cancer Agency Branch | Anti-influenza compounds |
US8673884B2 (en) * | 2008-02-05 | 2014-03-18 | Versitech Limited | Anti-influenza compounds |
US8530653B2 (en) | 2009-11-06 | 2013-09-10 | Chelsea Therapeutics, Inc. | Enzyme inhibiting compounds |
WO2011121309A1 (fr) | 2010-03-31 | 2011-10-06 | Takeda Pharmaceutical Company Limited | Dérivés phénylsulfonyle et leur utilisation comme antagonistes de l'histamine h3 |
US8658652B2 (en) | 2010-12-07 | 2014-02-25 | Chelsea Therapeutics, Inc. | Antifolate combinations |
WO2021078995A1 (fr) | 2019-10-25 | 2021-04-29 | Umc Utrecht Holding B.V. | Composé et test de blocage de la synthèse de polypeptides sélectif |
Also Published As
Publication number | Publication date |
---|---|
AU3276793A (en) | 1993-07-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100226114B1 (ko) | 항증식 작용을 가진 퀴나졸린 화합물 | |
JP2016532656A (ja) | Krasg12cの阻害剤 | |
CZ182792A3 (en) | Quinazoline derivatives, process of their preparation and pharmaceutical compositions containing said derivatives | |
TW202039490A (zh) | Mat2a之雜雙環抑制劑及用於治療癌症之使用方法 | |
DK157019B (da) | Analogifremgangsmaade til fremstilling af 2-amino-4-hydroxyquinazolinderivater | |
JP6319747B2 (ja) | 置換4−ピリドン及びそれらの好中球エラスターゼ活性阻害薬としての使用 | |
IE59309B1 (en) | New quinazoline derivatives, process for their production and pharmaceutical compositions comprising them | |
WO2003002567A1 (fr) | Pyrazolo[3,4-d]pyrimidines inhibant les infections par h. pylori | |
JP2003522761A (ja) | Cox−2の選択的阻害剤としてのピリミジン誘導体 | |
SG184766A1 (en) | Isothiazolo-pyrimidinedione derivatives as trpa1 modulators | |
CN103261156A (zh) | 用于治疗神经退化性疾病的新化合物 | |
JPS61282368A (ja) | 抗がん性キナゾリン誘導体 | |
JP2011042653A (ja) | アデノシン受容体リガンドとして有用なトリアゾロ−キノリン誘導体 | |
US4782055A (en) | Imidazopyridine compounds useful in the treatment of ulcers | |
WO1993013079A1 (fr) | Quinazolines anti-folates | |
US5574039A (en) | Antiproliferative compounds having nitrogen-containing tricyclic ring systems and phenyl substituents | |
CN101501007B (zh) | 喹唑啉衍生物 | |
KR920008832B1 (ko) | 항세포분열성(Antiproliferative) 고리화합물 | |
US11174255B2 (en) | Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases | |
EP0901473B1 (fr) | Derives de piperazinylalkylthiopyrimidine, compositions pharmaceutiques les contenant et leur procede de preparation | |
EP0550589A1 (fr) | Composes tricycliques substitues | |
JPH07316162A (ja) | 三環式化合物 | |
HRP920518A2 (en) | Antiproliferative substituted naphthalene compounds | |
CS218022B1 (cs) | Deriváty 2-piperazino-4-amino-6,7-dimethoxychinazolina a způsoby jejich přípravy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN MW NL NO NZ PL PT RO RU SD SE UA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |